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Objective: A twin pregnancy consisting of a complete hydatidiform mole with a coexisting normal fetus
is extremely rare with an incidence of 1/22,000 to 1/100,000. The incidence of preterm delivery is high
and few pregnancies reach near term with a viable fetus.
Case report: A 34-year-old woman presented at 20 weeks of gestation with increased levels of serum
beta human chorionic gonadotropin (beta-HCG) at 4.74 multiples of the median (310277.7 mIU/mL).
Ultrasonography showed a hydatidiform mole together with a normal fetus. Fetal karyotyping revealed
46XY. The serum beta-HCG levels were followed up throughout the remainder of the pregnancy. A male
infant weighting 2260 g and the molar tissue were delivered at 37 weeks of gestation. The karyotype of
the molar tissue showed 46XX and the histopathological report conﬁrmed our diagnosis. At 4 months
postpartum, metastatic gestational trophoblastic disease of the lung was diagnosed in the mother by a
computed tomography scan due to increased beta-HCG levels. The patient received three unsuccessful
cycles of methotrexate and folinate. Another four cycles of chemotherapy consisting of etoposide,
methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) were initiated and the beta-
HCG levels returned to normal. There was no evidence of recurrence in the subsequent 5 years of regular
follow up.
Conclusion: A pregnancy with a complete hydatidiform mole and a living cotwin can be a serious threat
to the health of both the mother and the fetus. Early diagnosis depends on a combination of detecting an
unusually high level of serum beta-HCG and ultrasound examination. We suggest that continuation of
the pregnancy may be an acceptable option and that the pregnancy may continue until term if a normal
fetal anatomy is assured and maternal complications are under control. Patients require careful post-
partum follow up and any recurrent disease should be managed aggressively.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Twin pregnancies consisting of a complete hydatidiform mole
with a coexisting normal fetus are extremely rare [1e7], accounting
for an incidence of 1/22,000 to 1/100,000 pregnancies. There is an
increased risk of maternal and fetal complications in twinnd Gynecology, Chang Gung
g Gung University College of
Taiwan.
uang).
bstetrics & Gynecology. Publishedpregnancies with one complete hydatidiform mole [8e11]. The
incidence of preterm delivery is high and few pregnancies reach
near term with a viable fetus. Careful evaluation of the risks of
maternal and fetal complications is crucial during the continuing
pregnancy.Case report
A 34-year-old woman, gravida 4, para 0, presented at 20 weeks
of gestation with increased levels of serum beta human chorionic
gonadotropin (beta-HCG) of up to 4.74 multiples of the medianby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Ultrasound scan at 20 weeks of gestation showing a live fetus and one hyda-
tidiform mole (arrows) located at the uterine fundus with a grape-like appearance.
PL ¼ normal placenta.
Fig. 2. Gross appearance of the hydatidiform mole (left) with grape-like tissue and
another normal placenta with umbilical cord (right).
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Down's syndrome. An ultrasound scan showed a normal fetus and a
coexisting, but separate, soft tissue mass with multiple cystic
spaces in the uterine fundus, measuring 7.5 cm  6.8 cm  5.4 cm
(Fig. 1). Amniocentesis for fetal karyotyping revealed 46XY. There
was no episode of vaginal bleeding nor evidence of hypertensionFig. 3. Log beta-human chorionic gonadotropin (beta-hCG) versus time curve during pregna
of gestation; (B) chemotherapy with three cycles of methotrexate; and (C) chemotherapy
vincristine.during the pregnancy. Ultrasound examination at 35 weeks of
gestation showed the normal fetus in a breech presentation and
appearing small for gestational age, whereas the hydatidiformmole
had grown to 12.2 cm  9.2 cm  3.0 cm in size. A male infant
weighing 2260 g was delivered by cesarean section at 37 weeks of
gestation and the accompanying molar tissue measuring 11 cm 
9.2 cm  3.0 cm at the uterine fundus was removed (Fig. 2). Kar-
yotyping of the molar pregnancy revealed 46XX and the histo-
pathological report conﬁrmed the diagnosis of a complete
hydatidiform mole with visible large hydropic villi and mild
trophoblastic proliferation.
The patient recovered well and her levels of serum beta-HCG
decreased to 995.3 mIU/mL 1 week later (Fig. 3). At 4 months
postpartum, however, she had symptoms of fatigue, dizziness, and
intermittent dyspnea. Her beta-HCG levels were rechecked and
were 268.1 mIU/mL. A computed tomography scan of her chest
showed a nodule (1.6 cm) over the left lower lung, suggestive of an
invasive metastatic mole lesion. The patient started chemotherapy
with three cycles of methotrexate and folinate when the initial
beta-HCG level was 601.2 mIU/mL. Subsequent serum beta-HCG
measurements showed a further increase to 2806 mIU/mL, indi-
cating resistance to methotrexate. Therefore a different chemo-
therapy regimen consisting of etoposide, methotrexate,
actinomycin D, cyclophosphamide, and vincristine (EMA-CO) was
prescribed. After four cycles of the EMA-CO regimen, the beta-HCG
levels were reduced and decreased to within the normal range
(<2.0 mIU/mL). There was no evidence of recurrent disease in the
following 5 years of follow up.
Discussion
Twin pregnancies consisting of a complete hydatidiform mole
with a coexisting normal fetus are rare [1e7], with an incidence
ranging from 1/22,000 to 1/100,000. These cases are usually
detected in the middle trimester by ultrasound examination and
further conﬁrmed by cytogenetic studies and histopathological
examination. In our patient, increased beta-HCG levels were noted
during maternal serum screening for Down's syndrome, which
prompted us to carry out a further evaluation to clarify the un-
derlying condition.
There is an increased risk of maternal and fetal complications in
twin pregnancies with one complete hydatidiform mole [8e11],
including vaginal bleeding, pre-eclampsia, hyperthyroidism, preg-
nancy termination, preterm birth, and spontaneous fetal loss [10].ncy, cesarean delivery, and chemotherapy treatment. (A) Cesarean section at 37 weeks
with four cycles of etoposide, methotrexate, actinomycin D, cyclophosphamide, and
Table 1









Delivery method Maternal complications
Anderson et al [1] 1 25 36 2750 Cesarean section Vaginal bleeding, gestational diabetes




One patient had preterm labor
Two patients had persistent gestational trophoblastic tumor
Johnston et al [6] 1 26 30 1410 Cesarean section Vaginal bleeding








One patient had vaginal bleeding, preterm labor and
metastatic gestational trophoblastic tumor






N/A One patient had persistent gestational trophoblastic tumor
Present report 1 34 37 2260 Cesarean section Metastatic gestational trophoblastic tumor
N/A ¼ not available.
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reach near term with a viable fetus (Table 1). A risk of persistent
gestational trophoblastic disease has been observed in some
studies. In one series, 12 of 22 (55%) patients with a complete mole
and a coexisting viable fetus developed persistent gestational
trophoblastic disease and required chemotherapy; ﬁve of these
patients developed metastatic disease requiring multiple cycles of
chemotherapy [8]. However, another study reported that the risk of
persistent trophoblastic disease after a pregnancy with a diploid
mole and a coexisting fetus is similar to that after a singleton molar
pregnancy and expectant management instead of therapeutic
abortion can be pursued [12].
In the past, immediate termination after the diagnosis of a twin
pregnancy with one complete hydatidiform mole has been sug-
gested due to the increased risk of developing persistent gesta-
tional trophoblastic disease and maternal complications.
Continuation of the pregnancy has recently become an acceptable
choice and several cases of continued pregnancy with a living fetus
have been reported [1e7] with successful management of compli-
cations. In a series of Japanese patients, researchers noted that the
rate of subsequent development of persistent trophoblastic tumors
was considerably higher in patients with a hydatidiform mole with
a coexisting live twin fetus than in patients with a single complete
mole [13]. However, as the risk of malignancy is unchanged with
advancement of gestational age, continued pregnancy may be
allowed in patients under conditions of well-controlled maternal
complications and a normal viable fetus [13]. In conclusion, if the
diagnosis is made close to fetal viability, continuation of the preg-
nancy is an acceptable option after extensive discussion and
agreement with the parents.
The most common metastatic site of gestational trophoblastic
disease is the lungs, which are affected in over 80% of patients. The
vagina is the second most common site of metastasis, accounting
for 30% of cases. Malignant gestational trophoblastic disease is very
sensitive to chemotherapy and a number of chemotherapy regi-
mens are used to treat the disease [14]. Early stage gestational
trophoblastic disease is often cured with single-agent chemo-
therapy. By contrast, advanced stage disease requires multi-agent
combination chemotherapeutic regimens to achieve a cure. EMA-
CO is the most commonly used combination chemotherapy to
treat high-risk gestational trophoblastic disease as it has the best
effectiveness to toxicity ratio. In a series of 272 women with high-
risk malignant gestational trophoblastic disease who were treated
with EMA/CO, 78% achieved complete remission [15]. In cases re-
fractory to EMA-CO or relapse from EMA/CO chemotherapy, re-
searchers reported that etoposide and cisplatin is an effective, but
moderately toxic, regimen for these patients [16,17].
In summary, a pregnancy with a complete hydatidiform mole
and a living cotwin can be a serious health threat to both the
mother and fetus. Early diagnosis depends on a combination ofdetecting an unusually high level of serum beta-HCG (perhaps
during maternal serum screening for Down's syndrome as in our
patient) and ultrasound examination. We suggest that the contin-
uation of the pregnancy may be an acceptable option and a pro-
longed pregnancy until term is likely if a normal fetal anatomy is
assured and any maternal complications are under control. Patients
are required to observe careful postpartum follow up and any
recurrent disease should be managed aggressively. Women with a
history of gestational trophoblastic disease are at increased risk of
developing subsequent gestational trophoblastic disease and
therefore their future pregnancies require careful monitoring to
ensure normal gestational development.Conﬂicts of interest
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